Vismodegib Patent Expiration
Vismodegib is Used for treating basal cell carcinoma and cancer in mammals. It was first introduced by Genentech Inc
Vismodegib Patents
Given below is the list of patents protecting Vismodegib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Erivedge | US9278961 | Pyridyl inhibitors of hedgehog signalling | Dec 15, 2028 | Genentech |
| Erivedge | US7888364 | Pyridyl inhibitors of hedgehog signalling | Nov 11, 2028 | Genentech |
| Erivedge | US9790183 | Pyridyl inhibitors of hedgehog signalling |
Sep 02, 2025
(Expired) | Genentech |
Vismodegib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vismodegib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | Dwight Owen | NA |
SUSPENDED
(Sep 1, 2026)
| PHASE1 |
| Vismodegib in Treating Patients With Advanced Chondrosarcomas | National Cancer Institute (NCI) | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma | Genentech, Inc. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE2 |
| Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) | National Cancer Institute (NCI) | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE2 |
| Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2 |